Intracoastal Capital Amends PharmaCyte Biotech Stake

TL;DR

**Intracoastal Capital just updated their PharmaCyte Biotech stake, watch for potential market reaction.**

AI Summary

Intracoastal Capital, LLC, along with Mitchell P. Kopin and Daniel B. Asher, filed an amended Schedule 13G/A on February 6, 2024, indicating a change in their beneficial ownership of PharmaCyte Biotech, Inc. common stock as of December 31, 2023. This amendment, number 3, shows that Mitchell P. Kopin is a reporting person. This matters to investors because it signals a potential shift in a significant shareholder's position, which could influence market sentiment or future corporate actions for PharmaCyte Biotech, Inc.

Why It Matters

Changes in significant shareholder positions can signal confidence or concern in a company's future, potentially impacting stock price and investor perception.

Risk Assessment

Risk Level: low — This filing is an amendment to a passive ownership report, indicating a change in a large holder's position, which is generally not a high-risk event.

Analyst Insight

Investors should monitor subsequent filings from Intracoastal Capital, LLC to understand the magnitude and direction of their ownership changes in PharmaCyte Biotech, Inc. and assess potential impacts on the stock.

Key Players & Entities

• Intracoastal Capital, LLC (company) — filer of the SC 13G/A
• PharmaCyte Biotech, Inc. (company) — subject company whose stock is being reported
• Mitchell P. Kopin (person) — reporting person and group member
• Daniel B. Asher (person) — group member
• December 31, 2023 (date) — date of event requiring the filing
• $0.0001 (dollar_amount) — par value per share of PharmaCyte Biotech, Inc. common stock

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of

Filing Documents

• ea192875-13ga3intra_pharma.htm (SC 13G/A) — 70KB
• 0001213900-24-010294.txt ( ) — 72KB

Ownership

Item 4. Ownership. (a) and (b): As of the close of business on December 31, 2023, each of Intracoastal and Mr. Kopin may have been deemed to have beneficial ownership of 903,412 shares of Common Stock, which consisted of (i) 475,884 shares of Common Stock held by Intracoastal and (ii) 427,528 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“ Intracoastal Warrant 1 ”), and all such shares of Common Stock represented beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 8,615,640 shares of Common Stock outstanding as of December 13, 2023, as reported by the Issuer, plus (2) 427,528 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 72,472 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock, (II) 129,147 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“ Intracoastal Warrant 2 ”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (III) 2,312,500 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal (

Certification

Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11. Page 6 of 7 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 6, 2024 /s/ Mitchell P. Kopin Mitchell P. Kopin /s/ Daniel B. Asher Daniel B. Asher Intracoastal Capital LLC By: /s/ Mitchell P. Kopin Mitchell P. Kopin, Manager Page 7 of 7

View Full Filing

View this SC 13G/A filing on SEC EDGAR